EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer

Leigh Ellis(Prostate Cancer Research), David P. Labbé(McGill University Health Centre)

Research Square

August 21, 2025

10.21203/rs.3.rs-7360528/v1

Cited by 0

Related Papers

Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma

|Nature Communications|2021|167

MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets

|Nature Communications|2022|148

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy

|Blood|2009|112

Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models

|Cancer Immunology Research|2014|90

Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation

|Cancer Cell|2025|20